Table 3.
CD47 antagonists currently entering clinical trials for treatment of hematological tumors
| Drug Name |
Other Name | Companies | Target-based Actions | Drug Classification | Indications | US Highest Phase | Chinese Highest Phase | NCT | CTR |
|---|---|---|---|---|---|---|---|---|---|
| AO-176 | AO-104 | Arch Oncology | CD47 antagonist | anti-CD47 monoclonal antibody | Multiple myeloma | Phase II | / | NCT04445701 | / |
| CC-90002 | INBRX-103 | Celgene Corp | CD47 antagonist | anti-CD47 monoclonal antibody | Acute myeloid leukaemia | Phase I | / | NCT02367196 | / |
| Myelodysplastic syndrome | Phase I | / | NCT02367196 | / | |||||
| GenSci-059 | GenSci-059 | GeneScience Pharmaceuticals Co Ltd | CD47 antagonist | anti-CD47 monoclonal antibody | Acute myeloid leukaemia | Phase I | / | NCT05263271 | / |
| Myelodysplastic syndrome | Phase I | NCT05263271 | / | ||||||
| Lemzoparlimab | TJ011133; TJC4 | I-Mab Bio-Tech (Tianjin) Co., Ltd | CD47 antagonist | anti-CD47 monoclonal antibody | Acute myeloid leukaemia | Phase II | Phase II | NCT04202003, NCT04912063 | CTR20210555, CTR20192522 |
| Myelodysplastic syndrome | Phase II | Phase III | NCT04202003, NCT04912063 |
CTR20210555, CTR20192522, CTR20230090 |
|||||
| Multiple Myeloma | Phase I | / | NCT04895410 | / | |||||
| Letaplimab | IBI-188 | Innovent Biologics Inc | CD47 antagonist | anti-CD47 monoclonal antibody | Acute myeloid leukaemia | Phase II | Phase II | NCT04485052 | CTR20200938 |
| Myelodysplastic syndrome | Phase I | Phase III | NCT04511975, NCT04485065 | CTR20201039 | |||||
| Ligufalimab | AK117 | Akeso Biopharma Inc | CD47 antagonist | anti-CD47 monoclonal antibody | Acute myeloid leukaemia | Phase II | Phase II | NCT04980885 | CTR20211305 |
| Myelodysplastic syndrome | Phase II | Phase II | NCT04900350 | CTR20210825 | |||||
| Magrolimab | Hu5F9-G4 | Gilead Sciences | CD47 antagonist | anti-CD47 monoclonal antibody | Myelodysplastic syndrome | Phase III | / | NCT04313881, NCT03527147 | / |
| Acute myeloid leukaemia | Phase III | / | NCT05263271, NCT04435691, NCT03248479, NCT03922477, NCT02678338 | / | |||||
| Myelodysplastic syndrome | Phase II | / | NCT05263271, NCT03248479, NCT02678338 | / | |||||
| ZL-1201 | ZL-1201 | Zai Lab Limited | CD47 antagonist | anti-CD47 monoclonal antibody | hematologic malignancies | Phase I | Phase I | NCT04257617 | CTR20210973 |
| IBI-322 | IBI-322 | Innovent Biologics Inc | CD47 antagonist; Programmed cell death ligand 1 inhibitor | bispecific antibody | Hematological neoplasm | Phase I | Phase I | NCT04795128 | CTR20210385 |
| Myeloid leukemia | Phase I | Phase I | NCT05148442 | CTR20213120 | |||||
| SIRPa-Fc-CD40L | SL-172154 | Shattuck Labs Inc | CD40 ligand receptor agonist; CD47 antagonist | bispecific antibody | Acute myeloid leukaemia | Phase I | NCT05275439 | / | |
| Myelodysplastic syndrome | Phase I | NCT05275439 | / | ||||||
| TG-1801 | NI-1701 | TG Therapeutics Inc | B-lymphocyte antigen CD19 modulator; CD47 antagonist; Immunoglobulin Fc receptor agonist | bispecific antibody | Chronic lymphocytic leukemia | Phase I | / | NCT04806035 | / |
| XL-114 | AU-341; AU7R-104; AUR-104 | Exelixis Inc | Bcl-10 protein modulator; CD47 antagonist; Caspase recruitment domain protein 11 modulator; Epidermal fatty acid binding protein inhibitor | bispecific antibody | Chronic lymphocytic leukemia | Phase I | / | NCT05144347 | / |
| DSP-107 | DSP-107 | KAHR Medical Ltd | CD47 antagonist; CDw137 agonist | SIRPα/Fc fusion protein antibody | Acute myeloid leukaemia | Phase I | / | NCT04937166 | / |
| Myelodysplastic syndrome | Phase I | NCT04937166 | / | ||||||
| Chronic myelomonocytic leukemia | Phase I | / | NCT04937166 | / | |||||
| Evorpacept | ALX-148 | ALX Oncology | SIRPα-Fc fusion protein,SIRPα/CD47 blocker | SIRPα/Fc fusion protein antibody | Acute myeloid leukaemia | Phase II | / | NCT04755244 | / |
| Myelodysplastic syndrome | Phase II | / | NCT04417517 | / | |||||
| IMM-01 | IMM-01 | ImmuneOnco Biopharm Co Ltd | CD47 antagonist | SIRPα/Fc fusion protein antibody | Acute myeloid leukaemia | Phase II | Phase II | NCT05140811 | CTR20212227, CTR20212519 |
| Myelodysplastic syndrome | Phase II | Phase II | NCT05140811 | CTR20212227, CTR20212519 | |||||
| Multiple myeloma | / | Phase II | / | CTR20212227 | |||||
| TTI-621 | TTI-621 | Trillium Therapeutics Inc | CD47 antagonist; Immunoglobulin gamma Fc receptor agonist | SIRPα/Fc fusion protein antibody | Multiple myeloma | Phase I | NCT05139225 | / | |
| Hematological neoplasm | Phase II | / | NCT02663518 | / | |||||
| TTI-622 | TTI-622 | Trillium Therapeutics Inc | CD47 antagonist; Immunoglobulin gamma Fc receptor agonist | SIRPα/Fc fusion protein antibody | Acute myelogenous leukemia | Phase I | / | NCT03530683 | / |
| Multiple myeloma | Phase I | / | NCT03530683, NCT05139225 | / | |||||
| Multiple myeloma | Phase I | / | NCT03530683 | / |